[go: up one dir, main page]

GB202306256D0 - 5-Methoxy-N,N-Dimethyltryptamine Formulations - Google Patents

5-Methoxy-N,N-Dimethyltryptamine Formulations

Info

Publication number
GB202306256D0
GB202306256D0 GBGB2306256.5A GB202306256A GB202306256D0 GB 202306256 D0 GB202306256 D0 GB 202306256D0 GB 202306256 A GB202306256 A GB 202306256A GB 202306256 D0 GB202306256 D0 GB 202306256D0
Authority
GB
United Kingdom
Prior art keywords
dimethyltryptamine
methoxy
formulations
dimethyltryptamine formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2306256.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Priority to GBGB2306256.5A priority Critical patent/GB202306256D0/en
Publication of GB202306256D0 publication Critical patent/GB202306256D0/en
Priority to PCT/GB2024/051133 priority patent/WO2024224115A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2306256.5A 2023-04-27 2023-04-27 5-Methoxy-N,N-Dimethyltryptamine Formulations Ceased GB202306256D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2306256.5A GB202306256D0 (en) 2023-04-27 2023-04-27 5-Methoxy-N,N-Dimethyltryptamine Formulations
PCT/GB2024/051133 WO2024224115A1 (en) 2023-04-27 2024-04-29 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2306256.5A GB202306256D0 (en) 2023-04-27 2023-04-27 5-Methoxy-N,N-Dimethyltryptamine Formulations

Publications (1)

Publication Number Publication Date
GB202306256D0 true GB202306256D0 (en) 2023-06-14

Family

ID=86691874

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2306256.5A Ceased GB202306256D0 (en) 2023-04-27 2023-04-27 5-Methoxy-N,N-Dimethyltryptamine Formulations

Country Status (2)

Country Link
GB (1) GB202306256D0 (en)
WO (1) WO2024224115A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3007992B1 (en) 2013-07-05 2018-01-26 Aptar France Sas DEVICE FOR DISPENSING FLUID OR PULVERULENT PRODUCT.
US20220071958A1 (en) * 2019-02-22 2022-03-10 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
FR3098407B1 (en) 2019-07-10 2024-12-13 Aptar France Sas Nasal Powder Dispensing Device
EP4595962A3 (en) 2020-06-12 2025-10-22 Beckley Psytech Limited Pharmaceutical composition
FR3117046B1 (en) 2020-12-09 2023-02-10 Aptar France Sas Powder dose dispensing device
FR3119772B1 (en) 2021-02-15 2024-06-14 Aptar France Sas Dispensing head for nasal dispensing device for a fluid or powder product
FR3121047B1 (en) 2021-03-29 2023-07-14 Aptar France Sas Nasal powder delivery device
AU2023244452A1 (en) * 2022-03-27 2024-11-07 GH Research Ireland Limited Treatment of cognitive dysfunction
EP4499074A1 (en) * 2022-03-27 2025-02-05 GH Research Ireland Limited 5-meo-dtm for the treatment of bipolar disorder

Also Published As

Publication number Publication date
WO2024224115A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
IL285537A (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
IL288617A (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
IL285539A (en) Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
EP4595962A3 (en) Pharmaceutical composition
GB202308830D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
IL315902A (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of psychomotor retardation
IL315905A (en) 5-methoxy-n.n-dimethyltryptamine for the treatment of psychomotor retardation
GB202306256D0 (en) 5-Methoxy-N,N-Dimethyltryptamine Formulations
GB202316902D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
GB202315176D0 (en) 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) formulations
GB202314993D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
GB202400703D0 (en) 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) formulations
GB202505025D0 (en) Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
PL3902541T3 (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40107577A (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
HK40065798A (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
IL315894A (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
HK40103232A (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40065799A (en) Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
GB202318153D0 (en) Antineoplastic combinations
IL321617A (en) Bezuclastinib formulations
GB202315863D0 (en) Formulations
GB202307059D0 (en) Formulations
GB202216961D0 (en) 5-meo-mt formulations
GB202314622D0 (en) Photodiodes

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)